F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress

Sunil K. Malonia  
*University of Massachusetts Medical School, Sunil.Malonia@umassmed.edu*

Parul Dutta  
*University of Pune*

Manas Kumar Santra  
*University of Pune*

*See next page for additional authors*

Follow this and additional works at: [http://escholarship.umassmed.edu/mccb_pubs](http://escholarship.umassmed.edu/mccb_pubs)

Part of the [Cancer Biology Commons](http://escholarship.umassmed.edu/mccb_pubs), [Cell Biology Commons](http://escholarship.umassmed.edu/mccb_pubs), [Molecular Biology Commons](http://escholarship.umassmed.edu/mccb_pubs), and the [Molecular Genetics Commons](http://escholarship.umassmed.edu/mccb_pubs)

**Recommended Citation**

[http://escholarship.umassmed.edu/mccb_pubs/28](http://escholarship.umassmed.edu/mccb_pubs/28)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Molecular, Cell and Cancer Biology Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress

Authors
Sunil K. Malonia, Parul Dutta, Manas Kumar Santra, and Michael R. Green

Keywords
DNA damage, FBXO31, MDM2, p53, tumor suppressor

Comments
Publisher PDF posted as allowed by the publisher’s author rights policy at http://www.pnas.org/site/aboutpnas/authorfaq.xhtml.

Rights and Permissions
Citation: Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8632-7. doi: 10.1073/pnas.1510929112. Epub 2015 Jun 29. Link to article on publisher’s site

This article is available at eScholarship@UMMS: http://escholarship.umassmed.edu/mccb_pubs/28
F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress

Sunil K. Malonia\textsuperscript{a,1}, Parul Dutta\textsuperscript{b}, Manas Kumar Santra\textsuperscript{b,1,2}, and Michael R. Green\textsuperscript{a,2}

\textsuperscript{a}Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605; \textsuperscript{b}National Centre for Cell Science, University of Pune Campus, Ganeshkhind, Pune, Maharashtra 411007, India; and \textsuperscript{1}Howard Hughes Medical Institute, University of Massachusetts Medical School, Worcester, MA 01605

Contributed by Michael R. Green, June 4, 2015 (sent for review May 28, 2015; reviewed by Sanjeev Das and Kevin Struhl)

The tumor suppressor p53 plays a critical role in maintaining genomic stability. In response to genotoxic stress, p53 levels increase and induce cell-cycle arrest, senescence, or apoptosis, thereby preventing replication of damaged DNA. In unstressed cells, p53 is maintained at a low level. The major negative regulator of p53 is MDM2, an E3 ubiquitin ligase that directly interacts with p53 and promotes its polyubiquitination, leading to the subsequent destruction of p53 by the 26S proteasome. Following DNA damage, MDM2 is degraded rapidly, resulting in increased p53 stability. Because of the important role of MDM2 in modulating p53 function, it is critical to understand how MDM2 levels are regulated. Here we show that the F-box protein FBXO31, a candidate tumor suppressor encoded in 16q24.3 for which there is loss of heterozygosity in various solid tumors, is responsible for promoting MDM2 degradation. Following genotoxic stress, FBXO31 is phosphorylated by the DNA damage serine/threonine kinase ATM, resulting in increased levels of FBXO31. FBXO31 then interacts with and directs the degradation of MDM2, which is dependent on phosphorylation of MDM2 by ATM. FBXO31-mediated loss of MDM2 leads to elevated levels of p53, resulting in growth arrest. In cells depleted of FBXO31, MDM2 is not degraded and p53 levels do not increase following genotoxic stress. Thus, FBXO31 is essential for the classic robust increase in p53 levels following DNA damage.

p53 | MDM2 | FBXO31 | DNA damage | tumor suppressor

One of the most fundamental and extensively studied anticancer mechanisms is the large increase in the levels of the tumor suppressor p53 that occurs following DNA damage (reviewed in ref. 1). The increased p53 then mediates growth arrest and/or apoptosis. The importance of this anticancer mechanism is highlighted by the mutation or functional inactivation of the p53 gene in more than 50% of human cancers (2, 3).

In unstressed cells, p53 is maintained at a low level. The major negative regulator of p53 is MDM2, an E3 ubiquitin ligase that interacts directly with p53 and promotes its polyubiquitination, leading to the subsequent destruction of p53 by the 26S proteasome (reviewed in ref. 4). Following DNA damage, MDM2 is degraded rapidly, resulting in increased p53 stability. Originally it was proposed that MDM2 degradation was caused by auto-ubiquitination; however, subsequent experiments showed that the E3 ubiquitin ligase activity of MDM2 is not required for its degradation (5).

We originally identified the F-box protein FBXO31 in an RNAi screen as one of 17 factors required for oncogenic BRAF to induce senescence in primary human cells (6). F-box proteins are best known for their role as the substrate-recognition components of the SKP1/CUL1/F-box protein (SCF) class of E3 ubiquitin ligases (7). The F-box motif is responsible for the ability of F-box proteins to interact with the SCF complex and to promote ubiquitination of their targets (8).

One of the other genes we isolated in our original RNAi screen was p53 (6), raising the possibility that FBXO31 and p53 function in a common pathway(s). Consistent with this idea, both FBXO31 and p53 can induce growth arrest (9, 10), and we have found that after DNA damage there is a posttranslational increase of FBXO31 levels, as there is for p53 (9). These considerations prompted us to ask whether there was a functional relationship between FBXO31 and p53.

Results

FBXO31 Is Required for Decreased MDM2 and Increased p53 Levels Following DNA Damage. We asked whether the ability of FBXO31 to induce growth arrest results, at least in part, from the regulation of p53 levels. Toward this end, p53-positive MCF7 cells expressing either a control nonsilencing (NS) shRNA or an FBXO31 shRNA were treated with the DNA-damaging agent camptothecin or γ-irradiation, and the levels of p53 and MDM2 were analyzed by immunoblotting. Previous studies have shown that MDM2 levels decrease rapidly following genotoxic stress (4), and therefore in the first set of experiments we monitored the levels of p53 and other proteins at early times after the induction of DNA damage. Within 90 min following camptothecin (Fig. 1.4) or γ-irradiation (Fig. 1B) treatment of MCF7 cells expressing a control NS shRNA, FBXO31 levels increased, as was consistent with previous results from our laboratory (9) and others (11). This increase in FBXO31 levels was accompanied by decreased MDM2 levels and increased p53 levels, as expected. Following camptothecin or γ-irradiation treatment of FBXO31 knockdown (KD) cells, there was a marked reduction in FBXO31 levels, as expected, but, notably, MDM2 and p53 levels remained constant. Similar results were obtained by the authors.

Significance

The tumor suppressor protein p53 plays a critical role in protecting humans from cancer. In response to cellular stresses, such as DNA damage, p53 levels increase and induce a variety of protective biological responses. In unstressed cells, p53 is maintained at a low level by MDM2, a protein that interacts with p53 and promotes its degradation. Following DNA damage, MDM2 is degraded rapidly, resulting in increased p53 levels.

Because of the essential role of MDM2 in modulating p53 function, it is critical to understand how MDM2 levels are regulated. Here we show that, following DNA damage, the F-box protein FBXO31, a potential tumor suppressor, is responsible for promoting MDM2 degradation and therefore is essential for the increase in p53 levels.


Reviewers: S.D., National Institute of Immunology, India; and K.S., Harvard Medical School.

The authors declare no conflict of interest.

\textsuperscript{1}S.K.M. and M.K.S. contributed equally to this work.

\textsuperscript{2}To whom correspondence may be addressed. Email: manas@nccs.res.in or Michael.Green@umassmed.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1510929112/-/DCSupplemental.
in p53-positive IMR90 cells (Fig. S1A and B) and using a second, unrelated FBXO31 shRNA (Fig. S1C–E).

A previous study suggested that following DNA damage the apparent decrease in MDM2 levels as monitored by immunoblotting in actuality is caused not by MDM2 degradation but rather by a conformational change in MDM2 that results in the masking of epitopes recognized by monoclonal anti-MDM2 antibodies (12) such as the AB1 antibody used in the experiments shown in Fig. 1A and B and Fig. S1A and B. Although this conclusion has been challenged by other studies (13), we performed two additional experiments to confirm that MDM2 is truly degraded following DNA damage in control but not in FBXO31 KD cells. First, in the experiments described above, MDM2 levels also were monitored using a polyclonal anti-MDM2 antibody (N20). Similar to the results with the AB1 monoclonal anti-MDM2 antibody, we found that after DNA damage MDM2 levels decreased in cells expressing the control NS shRNA but not in FBXO31 KD cells (Fig. 1A and B and Fig. S1A and B). Second, we ectopically expressed an N-terminal Flag-tagged MDM2 in control or FBXO31 KD MCF7 cells and, after DNA damage, monitored MDM2 levels using an anti-Flag antibody. The immunoblot results of Fig. 1C show that after camptothecin treatment in control MCF7 cells, the levels of ectopically expressed Flag-MDM2 decreased, and this decrease was accompanied by increased levels of endogenous p53. In contrast, after camptothecin treatment in FBXO31 KD cells, the levels of ectopically expressed Flag-MDM2 and endogenous p53 were unaffected.

The finding that in FBXO31 KD cells p53 levels failed to increase following DNA damage suggested that growth arrest would not occur efficiently. To test this prediction, we measured the mitotic index of control and FBXO31 KD cells in the presence of nocodazole to trap cells in mitosis. After DNA damage, cells harboring p53 arrest in G2 and G1, whereas cells lacking p53 will progress through the cell cycle and enter mitosis (14).

These experiments were performed in p53-positive HCT116 cells, which previously have been shown to undergo p53-dependent growth arrest in a mitotic index assay (14). Similar to the other p53-positive cell lines analyzed above, in FBXO31 KD HCT116 cells, MDM2 levels did not decrease and p53 levels did not increase after DNA damage (Fig. S1F). The results shown in Fig. 1D demonstrate that at 18 and 24 h following γ-irradiation the mitotic index of FBXO31 KD HCT116 cells was markedly higher than that of control HCT116 cells expressing an NS shRNA. Notably, the difference in mitotic index between control and FBXO31 KD HCT116 cells correlated with levels of p53 and the p53 target p21 (Fig. S1G), which plays a critical role in p53-mediated growth arrest (15, 16).
half-life of MDM2 and a concomitant increase in the half-life of p53 (see also Fig. S4D).

**FBXO31 Interacts Directly with MDM2.** F-box proteins impart sub- 
strate specificity to the SCF ubiquitin ligase machinery by interacting directly with their protein targets (8). To test whether FBXO31 and MDM2 interact, we performed a series of coimmunoprecipitation experiments. First, MCF7 cells were stably transduced with a retrovirus expressing myc-tagged FBXO31, and FBXO31 was immunoprecipitated using an anti-myc antibody. Fig. 3A shows the presence of MDM2 in the FBXO31 immunoprecipitate, which was increased by lactacystin addition. The reciprocal coimmunoprecipitation experiment showed the presence of p53-FBXO31 in the MDM2 immunoprecipitate.

**The FBXO31–MDM2 Interaction Is Dependent on Phosphorylation of MDM2 by ATM.** Recognition by F-box proteins typically requires phosphorylation of the substrate, which serves as a signal for ubiquitin-dependent destruction (8). Fig. 3B shows that the FBXO31–MDM2 interaction was lost, as expected, after treatment of cell extracts with λ-phosphatase, which nonspecifically removes phosphoryl groups.

MDM2 is phosphorylated by several protein kinases including the DNA damage response-initiating kinase ATM (20, 21), AKT (22, 23), cyclin-dependent kinases (CDKs) (24), cas- 
sein kinase 1 (CK1) (25), and mammalian target of rapamycin/ 
S6K1 (mTOR) (26). We analyzed the effect of chemical inhibitors of these kinases on MDM2 levels in MCF7 cells after ectopic expression of FBXO31. Fig. 3C shows that treatment of cells with the two different ATM inhibitors, KU-55933 (27) and caffeine (28), resulted in a substantial increase in the levels of MDM2, indicating decreased FBXO31-directed degradation. In contrast, treatment of cells with inhibitors of the PI3K/AKT pathway, i.e., LY294002 (29), CDKs (CR8 (30), CK1 (D4476 (31)), or mTOR [rapamycin (32)], had either no or only a modest effect on MDM2 levels. Consistent with the results of a previous study (25), treatment with the CK1 inhibitor D4476 also increased MDM2 levels, but the effect was much less than that observed following ATM inhibition.

We have shown previously that FBXO31 itself is phosphorylated by ATM (9). Therefore, it remained possible that the loss of the FBXO31–MDM2 interaction following ATM inhibition was caused, at least in part, by a failure to phosphorylate FBXO31. To rule out this possibility, we analyzed an FBXO31 derivative containing a mutation within the ATM phosphorylation site that prevents phos- 
phorylation (FBXO31-SDM1) (9). Fig. 3D shows that wild-type FBXO31 and the FBXO31-SDM1 mutant interacted with MDM2 comparably.

Finally, we analyzed an MDM2 derivative in which all six ATM phosphorylation sites were mutated (MDM2-6A) (33). A plasmid expressing wild-type MDM2 or MDM2-6A was cotransfected with an FBXO31 expression plasmid into Mdm2−/−, p53−/− MEFS, and MDM2 levels were monitored by immunoblotting. As shown in Fig. 3E, FBXO31 failed to reduce MDM2-6A levels, confirming the essential role of ATM in FBXO31-directed degradation of MDM2.

The experiments described above were performed with ectopically expressed FBXO31 and/or MDM2. We next performed coimmunoprecipitation experiments in camptothecin-treated MCF7 cells to detect an interaction between endogenous FBXO31 and MDM2. The coimmunoprecipitation experiment in Fig. 3F shows that an interaction could be detected between endogenous FBXO31 and MDM2. The FBXO31–MDM2 interaction was lost following treatment of cell extracts with λ-phosphatase but was restored upon the addition of phosphatase inhibitors. Also, as is consistent with the results described above, Fig. 3G shows that the interaction between endogenous FBXO31 and MDM2 was lost following treatment of MCF7 cells with the ATM inhibitor KU-55933. Finally, the coimmunoprecipitation experiment in Fig. 3H shows that an ATM-dependent interaction between endogene- 
ous FBXO31 and MDM2 also could be detected in IMR90 cells.

**FBXO31 Directs Polyubiquitination of MDM2.** Typically, F-box pro- 
tens direct polyubiquitination of their substrates, resulting in proteasome-mediated degradation (7, 34). We performed a series of experiments to determine whether FBXO31 can direct poly-
ubiquitination of MDM2. In these experiments, cells were treated with the proteasome inhibitor MG132 to minimize degradation of polyubiquitinated proteins. In the first experiment, MCF7 cells
were cotransfected with plasmids expressing Flag-MDM2, HA-tagged ubiquitin, and either myc-FBXO31 or myc-FBXO31ΔF. Polyubiquitination of MDM2 was assessed by immunoprecipitation of Flag-MDM2 followed by immunoblotting for HA-ubiquitin. The results of Fig. 4A show that ectopic expression of FBXO31, but not FBXO31ΔF, resulted in polyubiquitination of MDM2. Similar results were obtained in a reciprocal coimmunoprecipitation experiment. Notably, FBXO31-directed polyubiquitination of MDM2 was lost after treatment of cells with the ATM inhibitor KU-55933 (Fig. S6A).

To confirm these results, we performed another in vivo ubiquitination experiment involving cotransfection of plasmids expressing Flag-MDM2, His-tagged ubiquitin, and either myc-FBXO31 or myc-FBXO31ΔF. His-ubiquitin-conjugated proteins were purified under stringent, denaturing conditions, followed by immunoblotting for Flag-MDM2. The results confirm that ectopic expression of FBXO31, but not FBXO31ΔF, resulted in polyubiquitination of MDM2 (Fig. S6B).

We also used this His-ubiquitin pull-down assay to confirm the antagonistic relationship of MDM2 and FBXO31 on polyubiquitination of p53. In p53-negative H1299 cells we ectopically expressed His-ubiquitin with GFP-p53 alone, GFP-p53 and Flag-MDM2, or GFP-p53 and Flag-MDM2, and myc-FBXO31. Polyubiquitinated p53 was detected by purifying His-ubiquitin-conjugated proteins followed by immunoblotting for GFP-p53. The results show that ectopic expression of MDM2 resulted in a substantial increase in polyubiquitination of p53, which was counteracted by the coexpression of FBXO31 (Fig. S6C).

The ubiquitination assays described above were performed with ectopically expressed proteins. We next performed an additional in vivo ubiquitination experiment to confirm that endogenous FBXO31 could polyubiquitinate endogenous MDM2. Extracts from untreated or camptothecin-treated MCF7 cells expressing either an NS or FBXO31 shRNA were immunoprecipitated with an anti-MDM2 antibody, and the immunoprecipitate was analyzed by immunoblotting with an anti-ubiquitin antibody. As expected, the results of Fig. 4B show that camptothecin treatment led to a large increase in polyubiquitinated MDM2. Notably, knockdown of FBXO31 substantially reduced the amount of polyubiquitinated MDM2 in camptothecin-treated cells. These results indicate that FBXO31 is required for polyubiquitination of MDM2 following DNA damage.

Finally, we performed an in vitro ubiquitination assay. Previous studies have shown that MDM2 has auto-ubiquitinating activity in vitro in the presence of an E1 ubiquitin-activating enzyme and E2 ubiquitin-conjugating enzyme (35, 36). Therefore, we used a previously described catalytically inactive MDM2 mutant, MDM2(C464A) (35). In addition to MDM2(C464A), the reaction mixtures contained or lacked the known cofactors (E1, E2, ubiquitin, and ATP), ATM, and the SCF/myc-FBXO31 complex purified from transfected 293T cells. The results in Fig. 4C show that in vitro polyubiquitination of MDM2(C464A) was dependent on the addition of the known cofactors, ATM, and the myc-SCF/FBXO31 complex.

**Discussion**

In this report we show an essential role for FBXO31 in MDM2 degradation following genotoxic stress that is summarized in the schematic model shown in Fig. 4D and discussed below. Following DNA damage, FBXO31 is phosphorylated by ATM, resulting in increased levels of FBXO31. FBXO31, as part of the SCF complex, then interacts directly with and mediates the degradation of MDM2, which is dependent on the phosphorylation of MDM2 by ATM.
FBXO31 is essential for the classic robust increase in p53 levels following DNA damage. We have shown previously that in p53-deficient SK-MEL-28 cells FBXO31 also can induce G1 arrest following DNA damage through interaction with and degradation of cyclin D1 (9). Thus, following genotoxic stress, FBXO31 can induce growth arrest through two independent pathways that differ with regard to both substrates and p53 dependence.

Previous studies have shown that in response to DNA damage, MDM2 degradation also is mediated by the F-box protein beta-transducin repeat containing E3 ubiquitin ligase protein (b-TRCP; also called BTRC) and requires phosphorylation of MDM2 by ATM. The decreased MDM2 results in increased levels of p53, which promotes growth arrest and senescence through transcriptional activation of p21 and other p53 target genes. Thus, FBXO31 is a tumor suppressor.

The decreased MDM2 results in increased levels of p53, which promotes growth arrest and senescence through transcriptional activation of p21 and other p53 target genes. Thus, FBXO31 is a tumor suppressor.

Materials and Methods
DNA replication and senescence assays are described in SI Materials and Methods.

Cell Lines and Culture. MCF7, IMR90, H1299, and 293T cells were obtained from ATCC and were grown as recommended. Cell lines stably expressing empty vector, myc-FBXO31, or myc-FBXO31ΔF were generated by retroviral transduction as described (9). Cells were treated with camptothecin (20 μM; Sigma) or γ-irradiation (20 Gy) for 45 or 90 min, MG132 (10 μM; Sigma) for 4 h, lactacystin (5 μM; Calbiochem) for 8 h; or KU-55933 (10 μM; Cayman Chemical), or rapamycin (5 μM; Calbiochem) for 24 h. FBXO31 KD cells were generated using lentiviral shRNAs (FBXO31-1, TGGTGTTGACATGGGACAGCAGCAAAGGTTTCATAATGGATTAGAAGGCCCAAGATGATTACACTTTAGGAAACCTTTGGCCTGGCTCCTGGGAGA and FBXO31-2, TGGTGTTGACAGTGAGGAGCCAGCGAAAGGTTTCATAATGGATTAGAAGGCCCAAGATGATTACACTTTAGGAAACCTTTGGCCTGGCTCCTGGGAGA) provided by Ze Ronai, Sanford-Burnham Medical Research Institute, La Jolla, CA) and a plasmid expressing GFP (pEGFPC1; Clontech), myc-FBXO31, or myc-FBXO31ΔF. Thirty hours later, cells were treated with cycloheximide (PCNA; (Santa Cruz), 6 μM; Sigma), Flag (Sigma), GFP (Santa Cruz), Proliferating cell nuclear antigen (PCNA; (Santa Cruz), 6×-His (Abcam), -actin (Sigma), and β-tubulin (Sigma).

Immunoblotting. Protein extracts were prepared and immunoblotting was performed as described (9) using the following antibodies: mouse monoclonal MDM2 (A81; Calbiochem), rabbit polyclonal MDM2 (N20; Santa Cruz), mouse monoclonal p53 (DO1; Santa Cruz), Flag-MDM2 (Bethyl Laboratories, Inc.), phospho-ATM Ser1981 (Cell Signaling), ATM (Cell Signaling), p21 (Cell Signaling), monoclonal p53 (DO1; Santa Cruz), BTRC (Bethyl Laboratories, Inc.), phos- b-TRCP (Cell Signaling), myc (Roche), Flag (Sigma), GFP (Santa Cruz), Proliferating cell nuclear antigen (PCNA; (Santa Cruz), 6×-His (Abcam), -actin (Sigma), and -tubulin (Sigma).

Mitotic Index. HCT116 cells were seeded on a coverslip (5 × 10^3 cells per 12-well plate) and were exposed on the following day to 10-Gy ionizing radiation (Co60 irradiator). Thirty minutes later, nocodazole (200 μM; Sigma) was added to the cells for 18 or 24 h, or, as a control, cells were left untreated (0 h time point). Cells then were collected, fixed with 3.7% (vol/vol) formaldehyde in PBS for 30 min at 37 °C, and washed three times in PBS. When all time points were collected, cells were permeabilized with chilled methanol, stained with Hoechst 33258 (10 mg/mL) in PBS, and washed three times in PBS. Nuclei were visualized by fluorescence microscopy (Olympus). Nuclei with condensed, evenly staining chromosomes were scored as mitotic. At least 200 cells were counted for each sample.

Cycloheximide Chase. For the experiments monitoring endogenous MDM2, MCF7 or IMR90 cells were infected with a lentivirus expressing an NS or FBXO31 shRNA and puromycin selected for 5 d. Cells then were treated with cycloheximide (100 μM; Sigma). For the experiments monitoring Flag-MDM2, MCF7 cells or 293T cells were co-transfected with a plasmid expressing Flag-MDM2 (provided by Ze’ev Ronai, Sanford-Burnham Medical Research Institute, La Jolla, CA) and a plasmid expressing GFP (pEGFP-C1; Clontech), myc-FBXO31, or myc-FBXO31ΔF. Thirty hours later, cells were treated with cycloheximide.
(100 µM). For experiments in MDM2−/−, p53−/− MEFs, cells were transfected with plasmids expressing GFP-p53 (Addgene), Flag-MDM2, and myc-FBXO31 in various combinations, and 30 h later, cells were treated with cycloheximide (50 µg/mL). Total cell extracts were prepared as described above and subjected to immunoblotting with Flag (Sigma), myc (Roche), GFP (FL Santa Cruz), and PCNA (Cell Signaling) antibodies. Band intensities were quantified using Image J software version 1.47v (NIH).

**qRT-PCR**. Total RNA was isolated and reverse transcription was performed as described (9), followed by qRT-PCR using MDM2 forward (5′-CATTTGCATGCTCAGAAGCT-3′) and reverse (5′-GGGCAAGTTATCCCCTC-3′) primers.

**Coimmunoprecipitation.** Coimmunoprecipitation assays were performed as described (9). Lactooycin (5 µM; Calbiochem) was added before 8 h for preparation of the protein extract. For γ-phosphatase treatment (Fig. 3F), whole-cell extract prepared from MCF7 cells treated with camptothecin (20 µM for 45 min) was equally divided into buffers A, B, and C. For A, we used 0.1 M NaPO4-NaHPO4, 0.01 M Tris–Cl (pH 8.0), 10 mM β-mercaptoethanol, and C (0.1 M NaPO4-NaHPO4, 0.01 M Tris–Cl (pH 6.3), 10 mM β-mercaptoethanol, and bound proteins were eluted with buffer D (200 µM imidazole, 0.15 M Tris–Cl (pH 6.7), 30% [vol/vol] glycerol, 0.72 M β-mercaptoethanol, 5% [wt/vol] SDS). The eluted proteins were analyzed by immunoblotting.

For the in vitro assay, extracts from MCF7 cells were treated with DMSO or camptothecin (25 µM for 45 min) and MDM2 (10 µM) before immunoprecipitation. In the in vitro ubiquitination assay was performed as described (9). Briefly, 293T cells were cotransfected with plasmids encoding myc-CUL1, myc-SKP1, myc-ROC1, and myc-FBXO31. Complexes containing FBXO31/CUL1/SP1/KROC were immunopurified from the cell lysate using anti-myc beads and were incubated with recombinant GST-MDM2(C464A) (provided by Allan Weissman, National Cancer Institute, Bethesda), purified recombinant active ATM (provided by Tanya Paull, University of Texas at Austin, Austin, TX), 0.1 mM E1 (Boston Biochem), 0.25 mM E2 (UBCH3A, Boston Biochem), and 2.5 µg/mL ubiquitin (Boston Biochem) in ubiquitin assay buffer (10 mM Tris (pH 7.5), 100 mM NaCl, 2.5 mM MgCl2, 2.5 mM ATP, 1 mM DTT, and 10 mM MnCl2) for 2 h at 30 °C, and were analyzed by immunoblotting.

**Statistical Analysis.** All quantitative data were collected from experiments performed in at least triplicate and are expressed as mean ± SD. Differences between groups were assessed using two-tailed Student t test using Microsoft Excel.

**ACKNOWLEDGMENTS.** We thank Jiandong Chen, Stephen Jones, Tanya Paull, Ze’ev Ronai, Allan Weissman, and Bert Vogelstein for providing reagents and Sara Debiller for editorial assistance. This work was supported in part by a Ramalingaswami Fellowship from the Department of Biotechnology, Ministry of Science and Technology, Government of India (to M.K.S.). M.R.G. is an investigator of the Howard Hughes Medical Institute.